Arvinas (ARVN) vs Autolus Therapeutics (AUTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Autolus Therapeutics (AUTL) has outperformed Arvinas (ARVN) over the past year, gaining 0.6% versus a loss of 23.0%. Over five years, AUTL leads with a -71.2% price change compared with -91.2% for ARVN. Arvinas is the larger company by market cap ($484.6 million vs $471.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | AUTL |
|---|---|---|
| Share price | $7.51 | $1.77 |
| Market cap | $484.55M | $471.11M |
| 1-day change | +0.81% | -2.21% |
| YTD return | -36.68% | -11.06% |
| 1-year return | -22.97% | +0.57% |
| 5-year return | -91.18% | -71.17% |
| P/E ratio (TTM) | 28.88 | — |
| EPS (TTM) | $0.26 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.51 | $2.58 |
| 52-week low | $6.97 | $1.18 |
| Distance from 52-week high | -48.24% | -31.40% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +85.49% | +393.22% |
| Average volume | 788.21K | 2.10M |
| Shares outstanding | 64.52M | 266.16M |
| Employees | 246 | 752 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUTL has outperformed ARVN by 23.5 percentage points over the past year.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
ARVN vs AUTL FAQ
Which is bigger, Arvinas or Autolus Therapeutics?
Arvinas (ARVN) is larger, with a market capitalization of $484.55M compared with $471.11M for Autolus Therapeutics (AUTL).
Which stock has performed better over the past year, ARVN or AUTL?
AUTL returned +0.57% over the past 12 months, compared with -22.97% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and Autolus Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Arvinas and Biotechnology: Biological Products (No Diagnostic Substances) for Autolus Therapeutics.